Skip to content
Adagrasib
Krazati (adagrasib) is a small molecule pharmaceutical. Adagrasib was first approved as Krazati on 2022-12-12. It is used to treat non-small-cell lung carcinoma in the USA. It is known to target GTPase KRas.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Krazati
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Adagrasib
Tradename
Company
Number
Date
Products
KRAZATIMirati TherapeuticsN-216340 RX2022-12-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
krazatiNew Drug Application2021-12-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
Agency Specific
FDA
EMA
Expiration
Code
ADAGRASIB, KRAZATI, MIRATI THERAPS
2029-12-12ODE-352
2027-12-12NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Adagrasib, Krazati, Mirati Theraps
106893772037-05-17DS, DPU-3490
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD002289262——7
Colorectal neoplasmsD015179211——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8085——19
Lung neoplasmsD008175C34.90—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colonic neoplasmsD003110C181————1
Pancreatic neoplasmsD010190EFO_0003860C251————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameADAGRASIB
INNadagrasib
Description
Adagrasib, sold under the brand name Krazati, is an anticancer medication used to treat non-small cell lung cancer. Adagrasib is an inhibitor of the RAS GTPase family. It is taken by mouth. It is being developed by Mirati Therapeutics.
Classification
Small molecule
Drug classKirsten rat sarcoma (KRAS) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N
Identifiers
PDB—
CAS-ID2326521-71-3
RxCUI—
ChEMBL IDCHEMBL4594350
ChEBI ID—
PubChem CID138611145
DrugBankDB15568
UNII ID8EOO6HQF8Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KRAS
KRAS
Organism
Homo sapiens
Gene name
KRAS
Gene synonyms
KRAS2, RASK2
NCBI Gene ID
3845
Protein name
GTPase KRas
Protein synonyms
c-K-ras, c-Ki-ras, c-Kirsten-ras protein, cellular c-Ki-ras2 proto-oncogene, cellular transforming proto-oncogene, K-Ras 2, K-ras p21 protein, Ki-Ras, Kirsten rat sarcoma viral oncogene homolog, Kirsten rat sarcoma viral proto-oncogene, oncogene KRAS2, PR310 c-K-ras oncogene, proto-oncogene GTPase, transforming protein p21, v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
Uniprot ID
Q96D10
Mouse ortholog
Kras (16653)
GTPase KRas (P32883)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 464 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1 adverse events reported
View more details